InvestorsHub Logo
Followers 53
Posts 1782
Boards Moderated 0
Alias Born 03/22/2015

Re: dr_lowenstein post# 292769

Saturday, 06/30/2018 11:05:41 PM

Saturday, June 30, 2018 11:05:41 PM

Post# of 402219

Five studies involving 208?248 CCB users were identified.









It is conjectured that isradipine's unique ability to cross the blood-brain barrier is why it is the CCB with the greatest neuro-protective effect in Parkinson's. Pretty slick. Can you imagine the cost of the STEADY-PD Phase 3 trial, a large 3 year study conducted in 50 research centers? And also the Phase 2 before that? Ten million dollars easy. Twenty five maybe? More? What a great benefit to Elite shareholders to have these trials funded by the NIH and Michael J. Fox Foundation.




U-S-A! U-S-A! U-S-A!











Call on God but row away from the rocks.

-Hunter S. Thompson

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News